Nomura Holdings
XENE icon

Nomura Holdings’s Xenon Pharmaceuticals XENE Stock Holding History

Nomura Holdings’s Portfolio XENE Stock Details XENE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-221,095
Closed -$7.91M – 1676
2023
Q1 		$7.91M Buy
+221,095
New +$8.17M 0.03% 428

Other funds holding XENE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Nomura Holdings's XENE Position: Q2 2023 in Review

Nomura Holdings sold out of Xenon Pharmaceuticals (XENE) in Q2 2023, closing a stake of 221,095 shares — an estimated $7.91M sold.

Nomura Holdings first reported a position in XENE in Q1 2023 and held it in 1 quarter. The position peaked at $7.91M in Q1 2023. 175 funds tracked by Wall St. Rank hold XENE as of Q2 2023.

  • Nomura Holdings reported no remaining Xenon Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
  • Nomura Holdings sold 221,095 Xenon Pharmaceuticals shares in Q2 2023, an estimated $7.91M.
  • Nomura Holdings first reported a position in Xenon Pharmaceuticals in Q1 2023 and held it in 1 quarter.
  • Nomura Holdings's Xenon Pharmaceuticals position peaked at $7.91M in Q1 2023.
  • 175 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q2 2023.

Based on Nomura Holdings's 13F filing for Q2 2023, filed 14 Aug 2023.